Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of CDP1 in Advanced Colorectal Cancer
NCT03491709Phase 1Completed
- Sponsor
- Dragonboat Biopharmaceutical
- Start
- Jul 2018
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of cdp1 in colorectal cancer (CRC) (2 arms), sponsored by Dragonboat Biopharmaceutical. Primary endpoint: Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time up to 59 Days. Started Jul 2018; status: completed.
02
Drugs
cdp1
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03491709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03491709.